期刊论文

Luo, D.;Guo, Z.

英文

Cancers

2072-6694

2022

14

24

6025-

10.3390/cancers14246025

Conceptualization, D.L. and Z.G.; formal analysis, H.P.; investigation, H.P.; writing—original draft preparation, X.W.; writing—review and editing, X.W.; supervision, Q.L.; funding acquisition, D.L., Z.G. and X.W. All authors have read and agreed to the published version of the manuscript. This study was supported by the Natural Science Foundation of Hunan Province (No.2018JJ2350), the key project of the Education Department of Hunan Province (No.19A419), and the 2021 Hunan Graduate Scientific Research Innovation Project (CX20210953), General Projects of National Natural Science Foundation of China:(82273236), Shenzhen Natural Science Foundation Project (JCYJ20220530141609021), Multi-omics liquid biopsy of lung cancer (JSGG20210802153410031), Development of biomarkers and diagnostic reagents for early gastric cancer, Shenzhen Nanshan District Science and Technology Plan Project (NS016), Research Start-up Fund for Discipline Leaders of Huazhong University of Science and Technology Union Shenzhen Hospital (YN2021002). The article processing charges were funded by Dixian Luo.

本校为第一机构

Simple Summary ctDNA is a small DNA fragment derived from tumor cells, which contains tumor-related genomic information, such as mutation, methylation, microsatellite instability, etc. It is an ideal biomarker for real-time monitoring of tumor development. This work mainly reviews the different sources of ctDNA, such as blood, urine, uncommon cerebrospinal fluid, ascites, etc. The most frequent mutation and methylation detection methods in ctDNA, such as the most commonly used high-throughput sequencing and innovative methods, combined with new materials in recent years, such as CRISPR-Cas sys...